GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
Seoul, Korea, & Redwood City, California, 10 October 2023 – GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its pipeline into fibrosis with the publication of a paper in Cell Communication and Signaling. The paper, authored in collaboration with Seoul National University’s School of Biological Sciences and Institute of Microbiology, supports the need to fully inhibit two signaling receptors, lysophosphatidic acid receptor 1 (LPA1) and CXCR4, for the effective treatment of Idiopathic Pulmonary Fibrosis (IPF).
